Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held an extensive meeting with a high-level delegation from the Chamber of Pharmaceutical Industry, headed by Dr. Gamal El-Laithy, Chairman of the Chamber. The meeting came within the framework of discussing the latest developments regarding the Drug Traceability Project and exploring ways to enhance its implementation within local factories and companies.

The meeting reviewed the project’s implementation progress, as it is considered one of the most important digital transformation initiatives in Egypt’s pharmaceutical system. The project aims to strengthen oversight of drug circulation, ensure the highest standards of transparency, and safeguard the safety of pharmaceutical products. Discussions also covered mechanisms of cooperation between the EDA and the Chamber to ensure the effective application of the system and to overcome any challenges faced by manufacturers during execution.

Dr. Ali El-Ghamrawy emphasized that the Drug Traceability Project represents a qualitative leap in Egypt’s pharmaceutical control system and constitutes one of the main pillars of the Authority’s digital transformation strategy to develop the pharmaceutical sector. He explained that the project aims to track the movement of medicines from manufacturing stages until they reach the patient, thereby ensuring strict control over the pharmaceutical supply chain, preventing the circulation of non-compliant or counterfeit products, and achieving the highest levels of transparency and drug safety.

El-Ghamrawy noted that the EDA is working to support manufacturers and pharmaceutical service providers in efficiently implementing the system by providing technical training, necessary guidance, and continuous communication with all relevant parties. He stressed that the project’s success depends on effective cooperation between the Authority, the Chamber of Pharmaceutical Industry, and all partners in the sector.

He also affirmed that the implementation of the traceability system enhances Egypt’s regional and international standing as a country with an integrated pharmaceutical system capable of keeping pace with the latest global systems for oversight, quality assurance, and patient safety.

For their part, representatives of the Chamber of Pharmaceutical Industry expressed their appreciation for the efforts of the EDA in supporting the national pharmaceutical industry and fostering continuous collaboration with manufacturers. They emphasized that the Drug Traceability Project is a strategic step toward developing the production and distribution system and ensuring the delivery of safe and effective medicines to patients.

They pointed out that the Chamber is working to facilitate coordination between local companies and the EDA to implement the system efficiently and to provide proposals that help overcome any technical or operational challenges during implementation. They added that this project will enhance the competitiveness of Egyptian pharmaceuticals in regional and international

markets and support the State’s efforts to achieve self-sufficiency and localization of drug manufacturing.

Attendees agreed that the application of the system represents a fundamental step toward building an integrated digital pharmaceutical oversight system that supports the national industry, enhances public confidence in Egyptian medicines, and consolidates Egypt’s position as a regional hub for pharmaceutical manufacturing and smart regulatory systems.

The meeting was attended on behalf of the Egyptian Drug Authority by:

· Dr. Tamer Elhossieny, Vice Chairman of the Egyptian Drug Authority

· Counselor Sherif Magdy, Vice President of the State Council and Legal Advisor to the EDA

· Dr. Amany Gawdat, Associate to the EDA Chairman and Supervisor of the Central Administration of the Chairman’s Office

· Dr. Osama Hatem, Associate to the EDA Chairman for Policy and International Cooperation and Supervisor of the Central Administration of Pharmaceutical Policies and Market Access

· Dr. Amira Mahjoub, Head of the Central Administration for Inspection on Pharmaceutical Institutions

· Col. Mohamed Tantawy, Supervisor of Digital Transformation and Automation Projects at the EDA

From the Chamber of Pharmaceutical Industry:

· Dr. Ashraf El-Khouly, Vice Chairman of the Chamber’s Board of Directors

· Dr. Mohy Hafez, Dr. Yousry Nawar, Dr. Ahmed Leila, Dr. Mohamed Ibrahim, Dr. Peter Mehanna, Dr. Yasser Fayed, Dr. Sayed Hendawy, Dr. Mohamed Amin, Dr. Amr Seif, and Dr. Samy Khalil, Members of the Chamber’s Board of Directors

· Counselor Mohamed Abdel Gawad, Legal Advisor to the Chamber

· Dr. Mohamed Sweilem, Dr. Sayed Kamal, Dr. Mostafa Awad, Dr. Mohamed Gamal, Dr. Omar Hesham, and Dr. Karim Samir, Representatives of the Chamber

· Dr. Ahmed Ismail, representing one of the multinational pharmaceutical companies